NEUP Neuphoria to merge with UK's Scancell in all-share deal, combined company heading to Nasdaq - Scancell shareholders end up owning
NEUP Neuphoria to merge with UK's Scancell in all-share deal, combined company heading to Nasdaq - Scancell shareholders end up owning ~85.5%, Neuphoria holders ~14.5% - Deal comes with up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+ - Neuphoria brings ~$19M cash but no active pipeline after its PTSD drug failed Phase 3 last October, now just a shell for the reverse merger - Neuphoria holders also get CVRs tied to legacy licensing deals, not the core Scancell story - Deal expected to close late Q4 2026, subject to shareholder votes on both sides
5% - Deal comes with up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+ - Neuphoria brings ~$19M cash but no active pipeline after its PTSD drug failed Phase 3 last October, now just a shell for the reverse merger - Neuphoria holders also get CVRs tied to legacy licensing deals, not the core Scancell story - Deal expected to close late Q4 2026, subject to shareholder votes on both sides